EP1651676A4 - THERAPY REINFORCING GLUCAN - Google Patents

THERAPY REINFORCING GLUCAN

Info

Publication number
EP1651676A4
EP1651676A4 EP04786081A EP04786081A EP1651676A4 EP 1651676 A4 EP1651676 A4 EP 1651676A4 EP 04786081 A EP04786081 A EP 04786081A EP 04786081 A EP04786081 A EP 04786081A EP 1651676 A4 EP1651676 A4 EP 1651676A4
Authority
EP
European Patent Office
Prior art keywords
glucan
composition
provides
cells
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04786081A
Other languages
German (de)
French (fr)
Other versions
EP1651676A2 (en
EP1651676B1 (en
Inventor
Nai-Kong V Cheung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcticzymes Technologies ASA
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of EP1651676A2 publication Critical patent/EP1651676A2/en
Publication of EP1651676A4 publication Critical patent/EP1651676A4/en
Application granted granted Critical
Publication of EP1651676B1 publication Critical patent/EP1651676B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition.
EP04786081.2A 2003-07-16 2004-07-16 Therapy-enhancing glucan Expired - Lifetime EP1651676B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/621,027 US7507724B2 (en) 2001-01-16 2003-07-16 Therapy-enhancing glucan
PCT/US2004/023099 WO2005018544A2 (en) 2003-07-16 2004-07-16 Therapy-enhancing glucan

Publications (3)

Publication Number Publication Date
EP1651676A2 EP1651676A2 (en) 2006-05-03
EP1651676A4 true EP1651676A4 (en) 2010-01-13
EP1651676B1 EP1651676B1 (en) 2018-03-14

Family

ID=34216281

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04786081.2A Expired - Lifetime EP1651676B1 (en) 2003-07-16 2004-07-16 Therapy-enhancing glucan

Country Status (9)

Country Link
US (11) US7507724B2 (en)
EP (1) EP1651676B1 (en)
JP (1) JP4903041B2 (en)
KR (1) KR101197327B1 (en)
CN (1) CN1823092B (en)
AU (1) AU2004266138C1 (en)
BR (1) BRPI0411982A (en)
CA (1) CA2536632C (en)
WO (1) WO2005018544A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1545208A4 (en) * 2002-08-13 2006-04-12 Biopolymer Engineering Inc METHODS OF USING BETA-GLUCAN AS RADIOPROTECTIVE AGENT
AU2003268486A1 (en) * 2002-09-04 2004-03-29 Biopolymer Engineering, Inc. Cancer therapy using whole glucan particles and antibodies
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
JP4577660B2 (en) * 2004-04-16 2010-11-10 味の素株式会社 Polysaccharide binding capacity measurement kit for peripheral blood mononuclear cells
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
ES2375995T3 (en) 2004-09-17 2012-03-08 University Of Massachusetts COMPOSITIONS AND THEIR USES FOR DEFICIENCIES OF LISOSOMAL ENZYME.
CA2605749C (en) * 2005-04-26 2015-06-30 Eisai Co., Ltd. Compositions and methods for cancer immunotherapy
EP1917019A2 (en) * 2005-05-03 2008-05-07 Biopolymer Engineering, Inc. Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
CN101184780B (en) 2005-05-05 2012-10-03 森馨香料公司 Preparation of β-glucan and mannan
EP1948245B1 (en) * 2005-10-24 2011-10-05 University of Massachusetts Compositions and their uses for gene therapy of bone conditions
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
WO2007084661A2 (en) * 2006-01-17 2007-07-26 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
JP6082174B2 (en) * 2006-11-06 2017-02-15 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ Immunomodulating composition and method of use thereof
WO2008130719A1 (en) * 2007-04-24 2008-10-30 University Of Louisville Therapeutic beta-glucan combinations
EP2222283A2 (en) 2007-10-29 2010-09-01 University of Massachusetts Yeast cell wall protein (ycwp) encapsulated multilayered nanoparticles for nucleic acid delivery (sirna)
US20110053855A1 (en) * 2008-02-19 2011-03-03 Novogen Research Pty Ltd. Ex vivo cell stimulation
NO2700405T3 (en) 2008-05-29 2018-09-01
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
EP2340309A2 (en) 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Neutral nanotransporters
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
EP3363462A1 (en) 2012-04-30 2018-08-22 Biothera, Inc. Compositions and methods for beta-glucan immunotherapy
AU2014305659B2 (en) * 2013-08-06 2018-10-18 Commonwealth Scientific And Industrial Research Organisation Wheat having high levels of beta-glucan
WO2016007876A1 (en) * 2014-07-10 2016-01-14 Biothera, Inc. Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
US10865245B2 (en) 2014-12-23 2020-12-15 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof
WO2016106004A1 (en) 2014-12-23 2016-06-30 Full Spectrum Genetics, Inc. Novel anti-b7h3 binding compounds and uses thereof
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
MX2019011664A (en) * 2017-03-28 2019-11-18 Cargill Inc Readily water-miscible beta-glucan suspensions.
JP7167059B2 (en) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション Local delivery of nucleic acid compounds
US10946038B2 (en) 2017-08-09 2021-03-16 Case Western Reserve University Cancer treatment using beta-(1-3)-(1-4)-glucan
EP4509185A3 (en) * 2018-04-24 2025-04-23 Memorial Sloan Kettering Cancer Center Methods of enhancing immunogenicity of poorly immunogenic antigen-specific vaccines using oral yeast beta-glucans
EP3858362A1 (en) 2020-01-29 2021-08-04 Pleuran, s.r.o. Beta-glucan for use in enhancement of anti-tumor immunity in remission
US11572420B1 (en) * 2021-07-30 2023-02-07 Tissue repair ltd Isolated biological polysaccharide compound, methods of use and methods of manufacture thereof
KR20250110348A (en) 2022-11-23 2025-07-18 제이제이알앤디 엘엘씨 Cancer cytotoxic exosome formulations and methods for use in cancer treatment
CN116004408A (en) * 2022-12-29 2023-04-25 浙江大学杭州国际科创中心 A kind of acetic acid tolerant yeast mutant and its preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250436A (en) * 1984-11-28 1993-10-05 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
WO2002058711A1 (en) * 2001-01-16 2002-08-01 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2004030613A2 (en) * 2002-09-04 2004-04-15 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975553A (en) * 1965-03-08 1976-08-17 Henri Griffon Deproteination of yeast cells
US3987166A (en) 1970-05-13 1976-10-19 Kaken Kagaku Kabushiki Kaisha Treatment of tumors with glucan compositions in mice and rats
FR2447193A1 (en) * 1979-01-25 1980-08-22 Unicler USE OF PICHIA OR PICHIA EXTRACTS AS A MEDICINE.
US4251519A (en) * 1979-07-30 1981-02-17 Anheuser-Busch, Incorporated Process for the prevention and reduction of elevated blood cholesterol and triglycerides levels
FR2477416A1 (en) * 1980-03-10 1981-09-11 Unicler USE OF HANSENULA OR EXTRACTS OF HANSENULA AS A MEDICINAL PRODUCT
DE3019614A1 (en) 1980-05-22 1981-12-03 Sankyo Co., Ltd., Tokyo Hydrolysed glucan with immunosuppressive activity - for use in treating cancer and arthritis
JPS6346436B2 (en) 1980-08-14 1988-09-14 Fujitsu Ltd
US4454289A (en) * 1981-03-06 1984-06-12 Takara Shuzo Co., Ltd. Polysaccharides having anticarcinogenic activity and method for producing same
US4477432A (en) * 1981-05-01 1984-10-16 Cutter Laboratories, Inc. Oral immune globulin
US4731245A (en) * 1983-12-29 1988-03-15 Kitasato Kenkyusho Vaccine, antigen and antibody for treating microorganisms of the MCLS-type streptococcus sanguis
US4992540A (en) * 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5037972A (en) * 1984-11-28 1991-08-06 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
CA1340080C (en) * 1985-03-11 1998-10-13 Dorothee Herlyn Human tumor therapy
US4900722A (en) * 1985-08-19 1990-02-13 Bioglucans, L.P. Methods and compositions for prophylactic and therapeutic treatment of infections
US4739046A (en) 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
JPS62252730A (en) 1986-01-16 1987-11-04 Takeda Chem Ind Ltd Antitumor agent
EP0281858B1 (en) * 1987-03-03 1991-07-17 Centre de Recherches en Physique des Plasmas High-power gyrotron for generating electromagnetic millimeter or submillimeter waves
JPS63307825A (en) 1987-06-08 1988-12-15 Nippon Beet Sugar Mfg Co Ltd Antitumor agent and production thereof
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5189028A (en) 1989-02-20 1993-02-23 Taito Co., Ltd. Composition and method to enhance the efficacy of a fish vaccine and to stimulate the immune system of fish
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
ATE153856T1 (en) 1989-09-08 1997-06-15 Alpha Beta Technology COMPOSITION FOR STIMULATING THE IMMUNE SYSTEM
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
CA2066172A1 (en) * 1989-09-08 1991-03-09 Alpha Beta Technology, Inc. Method for producing soluble glucans
US6020324A (en) * 1989-10-20 2000-02-01 The Collaborative Group, Ltd. Glucan dietary additives
US6143731A (en) * 1989-10-20 2000-11-07 The Collaborative Group, Ltd. Glucan dietary additives
US5223491A (en) 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
JP2911554B2 (en) 1990-06-25 1999-06-23 台糖株式会社 Antiviral agent
DE4107154A1 (en) * 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh MONOCLONAL ANTICOERPER AGAINST MELANOMA
JPH05805A (en) 1991-06-20 1993-01-08 Sumitomo Electric Ind Ltd Method for producing thin film by sol-gel method
EP0654045A4 (en) * 1992-08-05 1996-03-20 Bioglucans L P Improved method for preparing soluble glucans.
IT1256035B (en) * 1992-08-10 1995-11-21 Consiglio Nazionale Ricerche IMMUNOSTIMULATING ACTIVITY GLUCANS
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
US5519009A (en) * 1993-10-01 1996-05-21 Donzis; Byron A. Solubilized yeast glucan
NO300692B1 (en) 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilized branched β-1,3-glucan and its use, as well as the use of unsolubilized branched β-1,3-glucan
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5576015A (en) * 1995-03-02 1996-11-19 Donzis; Byron A. Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
US20030180254A1 (en) * 1995-05-26 2003-09-25 The Govt. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US6117850A (en) * 1995-08-28 2000-09-12 The Collaborative Group, Ltd. Mobilization of peripheral blood precursor cells by β(1,3)-glucan
US5614242A (en) * 1995-09-27 1997-03-25 Barkley Seed, Inc. Food ingredients derived from viscous barley grain and the process of making
JP2859843B2 (en) * 1996-03-08 1999-02-24 株式会社雪国まいたけ Antitumor substance extracted from Maitake
BR9708387A (en) 1996-03-28 2000-01-04 Genitrix Llc Process for vaccination of a mammal to a selected antigen, host and pathogenic cells, vaccine composition, nucleic acid, and engineered opsonin.
JPH09304714A (en) * 1996-05-10 1997-11-28 Canon Inc Scanning optics
WO1998039013A1 (en) 1997-03-04 1998-09-11 Peregrine Pharmaceutical, Inc. Composition and method for treating cancer and immunological disorders resulting in chronic conditions
US6096310A (en) * 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
US5980918A (en) 1997-10-24 1999-11-09 Brennen Medical, Inc. β-D-glucan topical composition
ATE364395T1 (en) 1998-04-10 2007-07-15 Andrew Lees CONJUGATE VACCINES TO PREVENT DENTAL CARIES
WO1999055715A2 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US7030101B2 (en) 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
DE69940371D1 (en) 1998-09-14 2009-03-19 Nabi Biopharmaceuticals Rockvi BETA-GLUCAN CONTAINING COMPOSITIONS AND SPECIFIC IMMUNOGLOBULINS
US6369216B1 (en) * 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
US6143883A (en) * 1998-12-31 2000-11-07 Marlyn Nutraceuticals, Inc. Water-soluble low molecular weight beta-glucans for modulating immunological responses in mammalian system
US7927612B2 (en) 2000-01-19 2011-04-19 Baofa Yu Combinations and methods for treating neoplasms
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US7297330B2 (en) 2000-02-04 2007-11-20 Thomas Jefferson University Low dose haptenized tumor cell and tumor cell extract immunotherapy
US20020009463A1 (en) 2000-02-23 2002-01-24 Jan Raa Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
IT1318403B1 (en) 2000-03-17 2003-08-25 Cooperativa Ct Ricerche Poly T POLYSACCHARID ESTERS OF N-DERIVATIVES OF GLUTAMIC ACID.
FR2808687B1 (en) 2000-04-27 2003-12-05 Goemar Lab Sa MEDICAMENT CONTAINING POLYSACCHARIDE SUBSTANCES FOR THE ACTIVATION OF APOPTOSIS
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
WO2002028905A2 (en) * 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies
US20020119928A1 (en) 2000-10-27 2002-08-29 Mcanalley Bill H. Dietary supplement compositions
CU22979A1 (en) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF TUMORS OVER-EXPRESSING RECEPTORS WITH KINASE ACTIVITY IN TYPOSINE WASTE
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
KR20040039195A (en) * 2001-04-27 2004-05-10 아지노모토 가부시키가이샤 Immunopotentiators
CN1394867A (en) 2001-07-06 2003-02-05 中国科学院生态环境研究中心 Medicinal oligose and its preparation method and medicine composition containing said oligose
CA2469406A1 (en) 2001-11-06 2003-05-15 Orient Cancer Therapy Co., Ltd. Anticancer compositions
KR20050043751A (en) 2001-11-06 2005-05-11 오리엔트 캔서 세라피 컴퍼니 리미티드 Anticancer compositions
CA2467378C (en) * 2001-12-11 2009-09-01 Ceapro Inc. Cereal beta glucan compositions, methods of preparation and uses thereof
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
EP1545208A4 (en) 2002-08-13 2006-04-12 Biopolymer Engineering Inc METHODS OF USING BETA-GLUCAN AS RADIOPROTECTIVE AGENT
US20060165700A1 (en) 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
US7671040B2 (en) 2003-09-23 2010-03-02 Laboratoires Goemar S.A. Chemotherapeutic antineoplastic treatment
US20050065114A1 (en) 2003-09-23 2005-03-24 Jean-Claude Yvin Therapeutical treatment with oligo-beta- (1,3) -glucans, drugs used in said treatment
US7070778B2 (en) 2003-10-30 2006-07-04 Laboratoire Goemar Sa Therapeutical combination against cancer
US20090169557A1 (en) 2004-05-10 2009-07-02 Biopolymer Engineering, Inc. D/B/A Biothera Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
CA2605749C (en) 2005-04-26 2015-06-30 Eisai Co., Ltd. Compositions and methods for cancer immunotherapy
EP1917019A2 (en) 2005-05-03 2008-05-07 Biopolymer Engineering, Inc. Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
KR100648194B1 (en) * 2005-07-27 2006-11-23 삼성전자주식회사 Manufacturing Method of Semiconductor Device
WO2007056870A1 (en) 2005-11-21 2007-05-24 The Governors Of The University Of Alberta Methods and compositions for pharmacologically controlled targeted immunotherapy
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
WO2007084661A2 (en) 2006-01-17 2007-07-26 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
CN101072482A (en) * 2006-05-12 2007-11-14 富准精密工业(深圳)有限公司 Radiating device and radiating system using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250436A (en) * 1984-11-28 1993-10-05 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
WO2002058711A1 (en) * 2001-01-16 2002-08-01 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2004030613A2 (en) * 2002-09-04 2004-04-15 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CHEUNG NAI-KONG V ET AL: "Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 8, no. 5, 1 May 2002 (2002-05-01), pages 1217 - 1223, XP002429133, ISSN: 1078-0432 *
CHEUNG N-K V ET AL: "Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, SPRINGER-VERLAG, BERLIN, DE, vol. 51, no. 10, 1 November 2002 (2002-11-01), pages 557 - 564, XP002297978, ISSN: 0340-7004 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992, ANDOH T: "EFFECTS OF PERVENOUS ADMINISTRATION OF LENTINAN AND CONCOMITANT PERENDOSCOPIC LOCALIZED INJECTION ON GASTRIC CARCINOMA IN ELDERLY PATIENTS", XP002555832, Database accession no. PREV199294122760 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1977, SHIIO T ET AL: "A study of the condition of additive use of immunotherapeutic agent, lentinan, and chemotherapeutic agent, cyclophosphamide", XP002555833, Database accession no. EMB-1979102109 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; August 2005 (2005-08-01), HAMURO JUNJI: "[Anticancer immunotherapy with perorally effective lentinan]", XP002555831, Database accession no. NLM16121931 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; January 1998 (1998-01-01), TAKITA M ET AL: "[Successful treatment of hepatic metastasis of gastric cancer with 5'-DFUR and Lentinan]", XP002555834, Database accession no. NLM9464340 *
GAN TO KAGAKU RYOHO. CANCER & CHEMOTHERAPY AUG 2005, vol. 32, no. 8, August 2005 (2005-08-01), pages 1209 - 1215, ISSN: 0385-0684 *
HERLYN D ET AL: "Stimulation of monoclonal antibody-dependent macrophage-mediated cytotoxicity against human tumors by lentinan", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD,NY, US, vol. 7, no. 3, 1 January 1985 (1985-01-01), pages 332, XP023842271, ISSN: 0192-0561, [retrieved on 19850101] *
JOURNAL OF JAPAN SOCIETY FOR CANCER THERAPY 1977 JP, vol. 15 TH CONGR., 1977, pages 436, ISSN: 0021-4671 *
KANEKO Y ET AL: "Activity of lentinan against cancer and AIDS", INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, BIOSCIENCE EDIPRINT INC., CAROUGE-GENEVA, CH, vol. 5, no. 4, 1 January 1989 (1989-01-01), pages 203 - 213, XP009125324, ISSN: 0255-9625 *
NICHIDAI IGAKU ZASSHI, vol. 51, no. 6, 1992, pages 587 - 596, ISSN: 0029-0424 *
SANO BUN ET AL: "Antitumor effects induced by the combination of TNP-470 as an angiogenesis inhibitor and lentinan as a biological response modifier in a rabbit spontaneous liver metastasis model", SURGERY TODAY, SPRINGER, JP, vol. 32, no. 6, 1 May 2002 (2002-05-01), pages 503 - 509, XP009125321, ISSN: 0941-1291, [retrieved on 20020501] *
TAKITA M ET AL: "Successful treatment of hepatic metastasis of gastric cancer with 5'-DFUR and Lentinan", GAN TO KAGAKU RYOHO - JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY, GAN TO KAGAKU RYOHO, TOKYO, JP, vol. 25, no. 1, 1 January 1998 (1998-01-01), pages 129 - 133, XP009125325, ISSN: 0385-0684 *

Also Published As

Publication number Publication date
CN1823092A (en) 2006-08-23
US7507724B2 (en) 2009-03-24
US9480700B2 (en) 2016-11-01
WO2005018544A3 (en) 2005-06-09
WO2005018544A2 (en) 2005-03-03
CA2536632A1 (en) 2005-03-03
AU2004266138A1 (en) 2005-03-03
US9211304B2 (en) 2015-12-15
EP1651676A2 (en) 2006-05-03
US20110195071A1 (en) 2011-08-11
US20130230535A1 (en) 2013-09-05
CA2536632C (en) 2011-09-20
BRPI0411982A (en) 2006-08-29
KR101197327B1 (en) 2012-11-05
US20170232099A1 (en) 2017-08-17
US10307479B2 (en) 2019-06-04
US20130183295A1 (en) 2013-07-18
US20040116379A1 (en) 2004-06-17
AU2004266138C1 (en) 2009-10-22
JP2007531700A (en) 2007-11-08
US7462607B2 (en) 2008-12-09
US20080193456A1 (en) 2008-08-14
EP1651676B1 (en) 2018-03-14
US20060188506A1 (en) 2006-08-24
US8633170B2 (en) 2014-01-21
US7704973B2 (en) 2010-04-27
AU2004266138B2 (en) 2009-02-19
US8791252B2 (en) 2014-07-29
KR20060112708A (en) 2006-11-01
JP4903041B2 (en) 2012-03-21
US20160166600A1 (en) 2016-06-16
US20060020128A1 (en) 2006-01-26
US20100216743A1 (en) 2010-08-26
WO2005018544A8 (en) 2005-11-10
CN1823092B (en) 2012-10-17
US20140335100A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
WO2005018544A8 (en) Therapy-enhancing glucan
EA200501702A1 (en) SUSTAINABLE TO MANIPULATION DOSAGE FORM FOR TRANSDERMAL INTRODUCTION
IL169896A0 (en) Methods and compositions for administering therapeutic and diagnostic agents
HUP0301405A2 (en) Compositions containing therapeutically active components having enhanced solubility
BR0008590A (en) Polymeric delivery agent, composition, unit dosage form, method for administering a biologically active agent to an animal requiring the agent, method for preparing a composition; it's composed
ECSP088962A (en) NEW HERBICIDES
BRPI0515850A (en) transport agents derived from cupredoxin and methods of using them
DE69531741D1 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
EA200801071A1 (en) METHODS AND COMPOSITIONS FOR APPLICATION FOR THE TREATMENT OF PATIENTS WITH POSITIVE ON AUTOANTIBODIES DISEASE
EA200501810A1 (en) COMPOSITION OF CONJUGATED MEDICINE
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
BR0316050A (en) Methods of treating, controlling or preventing specific cancer and disease associated with unwanted angiogenesis and reducing or preventing an adverse effect associated with the administration of a second active ingredient and with radiation therapy, hormone therapy, biological therapy, or immunotherapy in a patient. suffering from a specific cancer, pharmaceutical composition and kit
EA200601253A1 (en) PREVIOUSLY LINEAR FLOATING MEDICAL FORM OF FENTANILE FOR ORAL APPLICATION AND METHODS
ATE396967T1 (en) (5-(2-HYDROXY-4-CHLOROBENZOYL)VALERIC ACID AND SALTS THEREOF, AND COMPOSITIONS FOR DELIVERING ACTIVE INGREDIENTS CONTAINING THESE COMPOUNDS
BRPI0411319A (en) therapeutically active compounds and their use
EA200600128A1 (en) METHOD FOR THE DESTRUCTION OF CANCER CELLS (OPTIONS), PHARMACEUTICAL AGENTS (OPTIONS) AND A SET FOR ITS IMPLEMENTATION
WO2004091497A3 (en) Methods and compositions for increasing the anaerobic working capacity in tissues
Jain et al. Platelet‐rich plasma released from polyethylene glycol hydrogels exerts beneficial effects on human chondrocytes
CY1109537T1 (en) Peptides and Peptide Derivatives, PREPARATION OF THESE ALSO USE THESE FOR THE PREPARATION OF THERAPEUTIC AND / OR PREVENTIVE ACTIVE ACTION
ATE514718T1 (en) PEPTABODY FOR CANCER TREATMENT
ATE372145T1 (en) DELIVERANCE OF GENETIC MATTER TO A STIMULATION SITE
EA200800397A1 (en) TIZANIDINE COMPOSITIONS AND TREATMENT METHODS USING COMPOSITIONS
DK1509523T3 (en) Triazaspiro compounds useful for treating or preventing pain
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
MA27474A1 (en) VACCINE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060206

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/716 20060101ALI20091123BHEP

Ipc: A61K 39/395 20060101ALI20091123BHEP

Ipc: C08B 37/00 20060101AFI20051116BHEP

Ipc: A61K 39/39 20060101ALI20091123BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20091211

17Q First examination report despatched

Effective date: 20100406

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DR. ROLF ENGSTAD

Inventor name: CHEUNG, NAI-KONG, V.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHEUNG, NAI-KONG, V.

Inventor name: DR. ROLF ENGSTAD

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOTEC PHARMACON ASA

Owner name: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

Owner name: BIOTEC PHARMACON ASA

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/715 20060101ALI20170901BHEP

Ipc: A61K 39/39 20060101ALI20170901BHEP

Ipc: A61K 31/716 20060101ALI20170901BHEP

Ipc: A61K 39/44 20060101ALI20170901BHEP

Ipc: A61K 39/00 20060101ALI20170901BHEP

Ipc: A61K 31/739 20060101ALI20170901BHEP

Ipc: A61K 47/36 20060101ALI20170901BHEP

Ipc: C08B 37/00 20060101AFI20170901BHEP

Ipc: A61K 39/395 20060101ALI20170901BHEP

INTG Intention to grant announced

Effective date: 20170927

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 978793

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004052468

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 978793

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180615

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180614

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20180710

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20180711

Year of fee payment: 15

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004052468

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180716

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

26N No opposition filed

Effective date: 20181217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180716

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180731

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180716

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180731

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180731

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004052468

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20190716

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200201

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190716

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20040716